Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
219.30 K
Value Traded
24.12 K
Short % Float
-
Days to Cover
4.9
+6.36%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
SGMOQ Catalyst Timeline
Dated clinical, regulatory and corporate events for Sangamo Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sangamo Therapeutics, Inc.
7Total events
0Upcoming
3Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
▲Acquiredisaralgagene civaparvovecCorporate
PTC acquisition of Sangamo's Fabry program isaralgagene civaparvovec (ST-920) closed for $111M plus up to $100M milestones
Fabry diseasesource ↗
▲AcquiredST-506Corporate
Lilly acquisition of Sangamo's capsid delivery, zinc finger and MINT platforms and prion program ST-506 closed for $50M
prion diseasesource ↗
●Legal / SettlementCorporate
Court-supervised auction under Section 363 of U.S. Bankruptcy Code conducted
Past FDA Catalysts and PDUFA Decisions
How SGMOQ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 62%
Micro Cap(rank 426 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIVV003 Gene TherapiesCompletedNCT03653247 | Sickle Cell Disease | Phase 1/2 | COMPLETED | 7 | Jul 17, 2025 | ||||||
| TX200-TR101 BiologicsCompletedNCT04817774 | Kidney Transplant Rejection | Phase 1/2 | COMPLETED | 26 | Oct 16, 2025 | ||||||
| ST-920 Gene TherapiesCompletedNCT04046224 | Fabry Disease | Phase 1/2 | COMPLETED | 36 | Apr 10, 2025 | ||||||
| ST-400 Investigational product Gene TherapiesCompletedNCT03432364 | Transfusion Dependent Beta-thalassemia | Phase 1/2 | COMPLETED | 5 | Nov 17, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every SGMOQ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in SGMOQ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SGMOQ for Q2 2026. | ||||
Ownership Trends
SGMOQ Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
8.3M
Shares Sold Short
-2.1% vs prior count
4.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SGMOQ ranks across every disease it competes in
Competitive Position is a premium feature
See how SGMOQ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSGMOQ News
About Sangamo Therapeutics, Inc.
BIOPHARMAWATCH ELITE
Trade the next SGMOQ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime